Hantz Financial Services Inc. Grows Stake in Takeda Pharmaceutical Co. $TAK

Hantz Financial Services Inc. grew its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 14.5% in the 3rd quarter, Holdings Channel.com reports. The fund owned 260,174 shares of the company’s stock after acquiring an additional 32,933 shares during the period. Hantz Financial Services Inc.’s holdings in Takeda Pharmaceutical were worth $3,809,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Arjuna Capital grew its position in Takeda Pharmaceutical by 8.3% during the 3rd quarter. Arjuna Capital now owns 59,806 shares of the company’s stock valued at $876,000 after purchasing an additional 4,584 shares during the last quarter. Carrera Capital Advisors grew its holdings in shares of Takeda Pharmaceutical by 8.2% during the third quarter. Carrera Capital Advisors now owns 150,598 shares of the company’s stock valued at $2,205,000 after buying an additional 11,453 shares during the last quarter. SYM FINANCIAL Corp grew its holdings in shares of Takeda Pharmaceutical by 18.4% during the third quarter. SYM FINANCIAL Corp now owns 23,796 shares of the company’s stock valued at $348,000 after buying an additional 3,702 shares during the last quarter. Belpointe Asset Management LLC bought a new stake in shares of Takeda Pharmaceutical during the third quarter valued at approximately $149,000. Finally, Fortis Capital Advisors LLC purchased a new position in Takeda Pharmaceutical in the 3rd quarter worth approximately $149,000. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

TAK stock opened at $17.79 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.19 and a quick ratio of 0.65. Takeda Pharmaceutical Co. has a 1 year low of $12.99 and a 1 year high of $17.94. The company has a market cap of $56.59 billion, a P/E ratio of 74.11 and a beta of 0.02. The stock’s fifty day moving average price is $15.66 and its 200-day moving average price is $14.89.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, January 29th. The company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.07). The firm had revenue of $7.76 billion during the quarter, compared to the consensus estimate of $7.81 billion. Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.60%. On average, equities analysts forecast that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have commented on TAK. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Morgan Stanley started coverage on Takeda Pharmaceutical in a research report on Tuesday, January 13th. They set an “overweight” rating on the stock. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.